Vladimir Makarov

3PUBLICATIONS
36CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsInnate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (3)

|Sep 15, 2019
RIG-I activation is critical for responsiveness to checkpoint blockade.

Simon Heidegger, Alexander Wintges, Florian Stritzke

|May 04, 2019
Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response.

Rajarsi Mandal, Robert M Samstein, Ken-Wing Lee

|Dec 09, 2017
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy.

Diego Chowell, Luc G T Morris, Claud M Grigg

Pageof 1